Recent submissions

  • Genome-wide homozygosity signature and risk of Hodgkin lymphoma. 

    Sud, A; Cooke, R; Swerdlow, AJ; Houlston, RS (2015-01)
    Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is associated ...
  • Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience. 

    Okines, A; Irfan, T; Khabra, K; Smith, I; O'Brien, M; Parton, M; Noble, J; Stanway, S; Somaiah, N; Ring, A; Johnston, S; Turner, N (2017-08-22)
    Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients ...
  • Discordance between Oncotype DX Recurrance Score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer 

    Dodson, A; Okonji, D; Assersohn, L; Rigg, A; Sheri, A; Turner, N; Smith, I; Parton, M; Dowsett, M
  • Treating cancer with selective CDK4/6 inhibitors. 

    O'Leary, B; Finn, RS; Turner, NC
    Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...
  • Treating cancer with selective CDK4/6 inhibitors. 

    O'Leary, B; Finn, RS; Turner, NC (2016-07)
    Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...
  • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. 

    Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; Konde, A; Garcia-Murillas, I; Pemberton, HN; Frankum, J; Rafiq, R; Badham, N; Campbell, J; Gulati, A; Turner, NC; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-09)
    Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ...
  • Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. 

    Asghar, US; Barr, AR; Cutts, R; Beaney, M; Babina, I; Sampath, D; Giltnane, J; Lacap, JA; Crocker, L; Young, A; Pearson, A; Herrera-Abreu, MT; Bakal, C; Turner, NC (2017-06-12)
    Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes and investigated ...
  • Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. 

    Lee, JY; Garcia-Murillas, I; Cutts, RJ; De Castro, DG; Grove, L; Hurley, T; Wang, F; Nutting, C; Newbold, K; Harrington, K; Turner, N; Bhide, S (2017-09-05)
    BACKGROUND: Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPV+) locally advanced head and neck cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for ...
  • Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. 

    Chong, IY; Aronson, L; Bryant, H; Gulati, A; Campbell, J; Elliott, R; Pettitt, S; Wilkerson, P; Lambros, MB; Reis-Filho, JS; Ramessur, A; Davidson, M; Chau, I; Cunningham, D; Ashworth, A; Lord, CJ (2017-08-22)
    OBJECTIVE: Oesophageal cancer is the seventh most common cause of cancer-related death worldwide. Disease relapse is frequent and treatment options are limited. DESIGN: To identify new biomarker-defined therapeutic approaches ...
  • Targeting TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell death in centrosome amplified breast cancer cells. 

    Koo, C-Y; Giacomini, C; Reyes-Corral, M; Olmos, Y; Tavares, IA; Marson, CM; Linardopoulos, S; Tutt, AN; Morris, JDH (2017-08-22)
    Thousand-and-one amino acid kinases (TAOKs) 1 and 2 are activated catalytically during mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize a compound that inhibits TAOK1 and ...
  • Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. 

    Melin, BS; Barnholtz-Sloan, JS; Wrensch, MR; Johansen, C; Il'yasova, D; Kinnersley, B; Ostrom, QT; Labreche, K; Chen, Y; Armstrong, G; Liu, Y; Eckel-Passow, JE; Decker, PA; Labussière, M; Idbaih, A; Hoang-Xuan, K; Di Stefano, A-L; Mokhtari, K; Delattre, J-Y; Broderick, P; Galan, P; Gousias, K; Schramm, J; Schoemaker, MJ; Fleming, SJ; Herms, S; Heilmann, S; Nöthen, MM; Wichmann, H-E; Schreiber, S; Swerdlow, A; Lathrop, M; Simon, M; Sanson, M; Andersson, U; Rajaraman, P; Chanock, S; Linet, M; Wang, Z; Yeager, M; GliomaScan Consortium; Wiencke, JK; Hansen, H; McCoy, L; Rice, T; Kosel, ML; Sicotte, H; Amos, CI; Bernstein, JL; Davis, F; Lachance, D; Lau, C; Merrell, RT; Shildkraut, J; Ali-Osman, F; Sadetzki, S; Scheurer, M; Shete, S; Lai, RK; Claus, EB; Olson, SH; Jenkins, RB; Houlston, RS; Bondy, ML (2017-05)
    Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two ...
  • RAZOR: a phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in in pre-menopausal women at increased risk of breast cancer 

    Howell, A; Ashcroft, L; Fallowfield, L; Eccles, DM; Eeles, R; Brentnall, A; Dowsett, M; Cuzick, J; Greenhalgh, R; Affen, J; Bundred, N; Boggis, C; Motion, J; Sergeant, J; Adams, J; Evans, DG
  • Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. 

    Barrdahl, M; Rudolph, A; Hopper, JL; Southey, MC; Broeks, A; Fasching, PA; Beckmann, MW; Gago-Dominguez, M; Castelao, JE; Guénel, P; Truong, T; Bojesen, SE; Gapstur, SM; Gaudet, MM; Brenner, H; Arndt, V; Brauch, H; Hamann, U; Mannermaa, A; Lambrechts, D; Jongen, L; Flesch-Janys, D; Thoene, K; Couch, FJ; Giles, GG; Simard, J; Goldberg, MS; Figueroa, J; Michailidou, K; Bolla, MK; Dennis, J; Wang, Q; Eilber, U; Behrens, S; Czene, K; Hall, P; Cox, A; Cross, S; Swerdlow, A; Schoemaker, MJ; Dunning, AM; Kaaks, R; Pharoah, PDP; Schmidt, M; Garcia-Closas, M; Easton, DF; Milne, RL; Chang-Claude, J (2017-11-01)
    Investigating the most likely causal variants identified by fine-mapping analyses may improve the power to detect gene-environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified ...
  • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. 

    Lecarpentier, J; Silvestri, V; Kuchenbaecker, KB; Barrowdale, D; Dennis, J; McGuffog, L; Soucy, P; Leslie, G; Rizzolo, P; Navazio, AS; Valentini, V; Zelli, V; Lee, A; Amin Al Olama, A; Tyrer, JP; Southey, M; John, EM; Conner, TA; Goldgar, DE; Buys, SS; Janavicius, R; Steele, L; Ding, YC; Neuhausen, SL; Hansen, TVO; Osorio, A; Weitzel, JN; Toss, A; Medici, V; Cortesi, L; Zanna, I; Palli, D; Radice, P; Manoukian, S; Peissel, B; Azzollini, J; Viel, A; Cini, G; Damante, G; Tommasi, S; Peterlongo, P; Fostira, F; Hamann, U; Evans, DG; Henderson, A; Brewer, C; Eccles, D; Cook, J; Ong, K-R; Walker, L; Side, LE; Porteous, ME; Davidson, R; Hodgson, S; Frost, D; Adlard, J; Izatt, L; Eeles, R; Ellis, S; Tischkowitz, M; EMBRACE; Godwin, AK; Meindl, A; Gehrig, A; Dworniczak, B; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Hahnen, E; Hauke, J; Rhiem, K; Kast, K; Arnold, N; Ditsch, N; Wang-Gohrke, S; Wappenschmidt, B; Wand, D; Lasset, C; Stoppa-Lyonnet, D; Belotti, M; Damiola, F; Barjhoux, L; Mazoyer, S; GEMO Study Collaborators; Van Heetvelde, M; Poppe, B; De Leeneer, K; Claes, KBM; de la Hoya, M; Garcia-Barberan, V; Caldes, T; Perez Segura, P; Kiiski, JI; Aittomäki, K; Khan, S; Nevanlinna, H; van Asperen, CJ; HEBON; Vaszko, T; Kasler, M; Olah, E; Balmaña, J; Gutiérrez-Enríquez, S; Diez, O; Teulé, A; Izquierdo, A; Darder, E; Brunet, J; Del Valle, J; Feliubadalo, L; Pujana, MA; Lazaro, C; Arason, A; Agnarsson, BA; Johannsson, OT; Barkardottir, RB; Alducci, E; Tognazzo, S; Montagna, M; Teixeira, MR; Pinto, P; Spurdle, AB; Holland, H; KConFab Investigators; Lee, JW; Lee, MH; Lee, J; Kim, S-W; Kang, E; Kim, Z; Sharma, P; Rebbeck, TR; Vijai, J; Robson, M; Lincoln, A; Musinsky, J; Gaddam, P; Tan, YY; Berger, A; Singer, CF; Loud, JT; Greene, MH; Mulligan, AM; Glendon, G; Andrulis, IL; Toland, AE; Senter, L; Bojesen, A; Nielsen, HR; Skytte, A-B; Sunde, L; Jensen, UB; Pedersen, IS; Krogh, L; Kruse, TA; Caligo, MA; Yoon, S-Y; Teo, S-H; von Wachenfeldt, A; Huo, D; Nielsen, SM; Olopade, OI; Nathanson, KL; Domchek, SM; Lorenchick, C; Jankowitz, RC; Campbell, I; James, P; Mitchell, G; Orr, N; Park, SK; Thomassen, M; Offit, K; Couch, FJ; Simard, J; Easton, DF; Chenevix-Trench, G; Schmutzler, RK; Antoniou, AC; Ottini, L (2017-07-10)
    Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge- ...
  • Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. 

    Litchfield, K; Levy, M; Orlando, G; Loveday, C; Law, PJ; Migliorini, G; Holroyd, A; Broderick, P; Karlsson, R; Haugen, TB; Kristiansen, W; Nsengimana, J; Fenwick, K; Assiotis, I; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration; PRACTICAL Consortium; Bishop, DT; Reid, A; Huddart, RA; Shipley, J; Grotmol, T; Wiklund, F; Houlston, RS; Turnbull, C (2017-07)
    Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis ...
  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

    Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03-25)
    BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
  • Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. 

    Heindl, A; Sestak, I; Naidoo, K; Cuzick, J; Dowsett, M; Yuan, Y (2018-02-01)
    Background: Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor-negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well defined. ...
  • Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. 

    Sheri, A; Smith, IE; Hills, M; Jones, RL; Johnston, SR; Dowsett, M (2017-07)
    AIMS: To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone. ...

View more